Global Tardive Dyskinesia Treatment Market 2019-2023

The global tardive dyskinesia treatment market is forecasted to experience a meteoric rise by 2023 driven by the increasing R&D on VMAT2 inhibitors. Wondering how to make the most of this flourishing tardive dyskinesia industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global tardive dyskinesia treatment market. It also examines the competitive landscape and some key tardive dyskinesia treatment vendors that include F. Hoffmann-La Roche, Merck, and Neurocrine Biosciences.

Want to get a preview about how you can gain valuable insights from Technavio's market research report? Check out the latest facts about the tardive dyskinesia treatment industry

The global tardive dyskinesia treatment market is expected to grow at a CAGR of more than 4% during the forecast period

Tardive dyskinesia treatment industry growth is expected to accelerate over the next five years, driven by increasing use of antipsychotic drugs across the globe. There has been a significant rise in the administration of antipsychotic drugs which is resulting in growing prevalence of tardive dyskinesia. The higher consumption of antipsychotic drugs leads to various deformities which is expected to boost the growth of the global tardive dyskinesia treatment market. Also, the rising incidences of mental disorders is fueling the demand for tardive dyskinesia treatment around the world. Technavio's tardive dyskinesia treatment industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

The Americas dominated the tardive dyskinesia treatment market by region

The global tardive dyskinesia treatment market was dominated by the Americas with a market share of over 67%, followed by EMEA and APAC. However, APAC is expected to witness a faster growth than EMEA and the Americas over the period of forecast. In addition, the Americas will drive around 63% of the growth for the global tardive dyskinesia treatment industry, while EMEA and APAC are also predicted to contribute significantly to the incremental growth in the forecast period.

Get more value with Technavio's subscription platform! Gain easy access to all Technavio's reports, along with on-demand services. Start your 14-day FREE trial

F. Hoffmann-La Roche, Merck, and Neurocrine Biosciences are among the leading tardive dyskinesia treatment vendors

The global tardive dyskinesia treatment market is forecasted to grow reasonably fragmented with the existence of many international and regional vendors who offer tardive dyskinesia treatment. Most of the established companies in the global tardive dyskinesia treatment market are focused on investing heavily on the development of therapeutics for tardive dyskinesia treatment which will contribute to the growth of the market. Many international and regional vendors are vying for their share of the global tardive dyskinesia treatment market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• F. Hoffmann-La Roche
• Merck
• Neurocrine Biosciences
• Novartis
• Teva Pharmaceutical

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch